Phase 4 N=260 Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery
Atrial Fibrillation
Primary: Number of Participants Who Developed Postoperative Atrial Fibrillation — 33; 30 participants — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=3,054 Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
Influenza
Primary: Number of Subjects With at Least One Influenza-like-infection (ILI) Episode — 133; 243; 376; 125 Participants
Phase 4 N=267 Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Functional Residual Capacity (FRC) After 4 Weeks of Treatment — -0.162; -0.037 Liters — p=0.069
Phase 4 N=240 AngioSeal Versus Radial Approach in Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: First Occurrence of Access Site Related Ischemic or Bleeding Complication — 16; 15 Participants
Phase 4 N=50 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish
Foot Dermatoses
Primary: Measurement of Antifungal Activity of Loceryl Nail Lacquer — 53.6; 53.5 Milimeter
Phase 4 N=40 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
Phase 4 N=113 Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah Population
Periodontal Disease · Type 2 Diabetes Mellitus
Primary: Glycated Hemoglobin A1c — 8; 8.2 percentage of Glycated Hemoglobin A1c
Phase 4 N=277 MTX Discontinuation and Vaccine Response
Arthritis, Rheumatoid
Primary: Satisfactory Vaccination Responses Against 3 Antigens — 31.5; 22.7; 51; 46.2 percentage of responders
Phase 4 N=20 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer
Foot Dermatoses
Primary: Percent of "in Label" Adherent Subjects — 85; 60 percentage of participants
Phase 4 N=30 Vapocoolant Spray Used Prior to Intravenous (IV) Insertions
Pain
Primary: Pain Scale Using Visual Analog Scale — 1.13; 1.60 score on a scale
Phase 4 N=596 Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
Hepatitis B · Hepatitis A
Primary: Antibody Concentrations for Anti-hepatitis A Virus (Anti-HAV) and Anti-hepatitis B Surface (Anti-HBs) Antigens — 2746.5; 1153.9 mIU/mL
Phase 4 N=70 Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions
Gastrointestinal Diseases
Primary: Maximal Measured Plasma Concentration (Cmax) of Rabeprazole — 393.50; 415.83 Nanograms per milliliter
Phase 4 N=64 Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population
Hepatitis C
Primary: Number of Participants With Sustained Virological Response (SVR) — 49 Participants
Phase 4 N=18 Opiates and Benzodiazepines on Driving
Driving Behavior
Primary: SDLP — 35.2; 49.8; 50.0; 33.5 centimeters
Phase 4 N=42 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
Social Anxiety Disorder · Social Phobia · Alcohol Use Disorder
Primary: Social Anxiety Severity — 87; 93 units on a scale